Alfigen, Inc. Appoints New CEO.Business Editors/Health/Medical Writers PASADENA, Calif.--(BUSINESS WIRE)--April 21, 2003 Alfigen, Inc., a privately held genetic and esoteric testing company, announced today the appointment of Mr. R. Jeffrey Lanzolatta as Chief Executive Officer of the company, effective April 28, 2003. Mr. Lanzolatta succeeds Ahmed Alfi, who will remain as Chairman of the Board of Directors and will focus his efforts on new business development and strategic planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. . "We are very pleased that Jeff will be an integral part of the Alfigen team and I look forward to his leadership as we move forward with our growth and expansion plans. Jeff brings with him a wealth of knowledge and over 25 years of experience in the clinical laboratory industry. I believe this ushers in a new phase for Alfigen and is clearly one of the most exciting times in the 23-year history of the company," Mr. Alfi said. Prior to joining Alfigen, Mr. Lanzolatta served as President of Unilab Southern California Southern California, also colloquially known as SoCal, is the southern portion of the U.S. state of California. Centered on the cities of Los Angeles and San Diego, Southern California is home to nearly 24 million people and is the nation's second most populated region, , where he led the dramatic expansion of a small regional reference laboratory into the largest clinical laboratory in California performing more than 75,000 tests per day with annual sales in excess of $250 million. "I am very excited to join the company and help strengthen Alfigen's leadership position in genetic testing Genetic Testing Definition A genetic test examines the genetic information contained inside a person's cells, called DNA, to determine if that person has or will develop a certain disease or could pass a disease to his or her offspring. , the fastest-growing segment of the clinical laboratory industry. As we move the company forward, we will be pursuing several strategic growth opportunities in new geographic areas as well as new areas of service," Mr. Lanzolatta said. Alfigen, Inc. was established as the first private full-service cytogenetics cytogenetics /cy·to·ge·net·ics/ (-je-net´iks) the branch of genetics devoted to cellular constituents concerned in heredity, i.e. chromosomes. laboratory in the country and is currently one of the largest independent genetics service providers serving the medical community nationally and internationally. Alfigen's large network of genetic counselors provides support and education to patients. The laboratory offers a broad range of highly complex genetic tests, including cytogenetics (prenatal, postnatal postnatal /post·na·tal/ (-na´t'l) occurring after birth, with reference to the newborn. post·na·tal adj. Of or occurring after birth, especially in the period immediately after birth. and cancer) fluorescence in situ hybridization Fluorescence in situ hybridization (FISH) A technique for diagnosing DiGeorge syndrome before birth by analyzing cells obtained by amniocentesis with DNA probes. FISH is about 95% accurate. (FISH), molecular diagnostics, clinical chemistry and flow cytometry flow cytometry (flōˑ sī·t  ˑ·m . The company's mission -- to provide the highest quality and standards in clinical genetic services with efficient turnaround time (1) In batch processing, the time it takes to receive finished reports after submission of documents or files for processing. In an online environment, turnaround time is the same as response time. , cost-effective pricing and personalized service -- is reflected in all aspects of the company's work. Alfigen's success is based on its commitment to quality. More information about Alfigen, Inc. can be viewed at the company's website at www.alfigen.com. |
|
|||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion